Jin Kyung Choi

USPTO Granted Patents = 10 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 4.7

ph-index = 1

Forward Citations = 46(Granted Patents)

Company Filing History:

Suzhou Lekin Semiconductor Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2017-2024

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11951130 - Chimeric antigen receptor that binds HLA-DR and CAR-T cell (2024-04-09),

2. 11905334 - Anti-human VSIG4 antibodies and uses thereof (2024-02-20),

3. 11329097 - Semiconductor device having a first pad not overlapping first connection electrodes and a second pad not overlapping second connection electrodes in a thickness direction (2022-05-10),

4. 11013765 - Chimeric antigen receptor that binds HLA-DR and CAR-T cell (2021-05-25),

5. 10927183 - Anti-human VSIG4 antibodies and uses thereof (2021-02-23),

6. 10651345 - Light emitting device, light emitting device package including the device, and lighting apparatus including the package (2020-05-12),

7. 10546977 - Light emitting device, light emitting device package including the device, and lighting apparatus including the package (2020-01-28),

8. 10388830 - Light emitting device package and light emitting device comprising same (2019-08-20),

9. 10326056 - Light emitting device, light emitting device package including the device, and lighting apparatus including the package (2019-06-18),

10. 9680065 - Light emitting device and light emitting device package including the same (2017-06-13),

Title: Innovations by Jin Kyung Choi: Pioneering Advances in Immunotherapy

Introduction: Jin Kyung Choi, an accomplished inventor based in Seoul, South Korea, has made significant contributions to the field of immunotherapy through his innovative patents. With a total of 10 patents to his name, he is recognized for his cutting-edge research and development in antigen-binding molecules and antibody technologies.

Latest Patents: Among his latest inventions is the patent for a chimeric antigen receptor that binds to HLA-DR and CAR-T cells. This groundbreaking invention involves an antigen-binding molecule composed of various heavy and light chain variable regions defined by specific amino acid sequences. This invention is crucial for advancing T cell receptor technologies and related cell line expressions. Another notable patent includes the development of anti-human VSIG4 antibodies and their potential applications. While detailed descriptions accompany the patents, they serve to illustrate the innovative spirit of Choi's work, outlining various aspects, advantages, and modifications that define the invention's scope.

Career Highlights: Jin Kyung Choi's career has seen him associated with leading companies in the biotechnology field, including LG Innotek Co., Ltd. and Eutilex Co., Ltd. His experiences within these organizations have undoubtedly shaped his innovative journey and have provided him with a platform to enhance his research initiatives.

Collaborations: Throughout his career, Jin Kyung Choi has collaborated with notable colleagues, including Sang Youl Lee and Sung Ho Jung. These collaborations reflect a commitment to teamwork and synergistic innovation, highlighting the role that diverse expertise plays in the development of transformative technologies.

Conclusion: Jin Kyung Choi’s contributions to immunotherapy not only demonstrate his role as a leading inventor but also reflect the potential impact of his innovations on the future of medical science. With a robust portfolio of patents and a collaborative approach to research and development, he continues to be a driving force in the advancement of therapeutic technologies.

This text is generated by artificial intelligence and may not be accurate.